Avacostar - (PASS)
ConditionANCA-associated Vasculitis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorVifor Fresenius Medical Care Renal Pharma
About this trial
The Avacostar PASS is a non-interventional, multi-national, prospective cohort study that will collect data from 2 cohorts of patients: those treated with avacopan for active severe AAV, and a second cohort treated with a cyclophosphamide or rituximab-based induction regimen without avacopan for active severe AAV. The overall study duration is anticipated to be up to 7 years, including a recruitment period of approximately 3 years.
Eligibility criteria
Qualifiers
Diagnosis of AAV (MPA or GPA), as determined by the Investigator according to their usual practice.
Active, severe AAV at the time of commencing avacopan or non-avacopan SoC induction therapy, in the opinion of the Investigator.
Age ≥18 years of either sex.
Has provided written informed consent.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
500 Participants
are grouped into 2 trial groupsSponsors and collaborators
Source ClinicalTrials.gov